Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
81 hedge funds and large institutions have $61.4M invested in Merrimack Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 12 closing their positions.
127% more call options, than puts
Call options by funds: $436K | Put options by funds: $192K
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
4% more funds holding
Funds holding: 78 → 81 (+3)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
17% less capital invested
Capital invested by funds: $74M → $61.4M (-$12.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.44M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.77M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.25M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$693K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$575K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$2.33M |
| 2 |
Millennium Management
New York
|
-$768K |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$681K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$584K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$171K |
MACK Hedge Fund Activity: Q1 2018 in Review
81 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2018, worth a combined $61.4M — down 17% from $74M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MACK positions and 12 closed out — a net gain of 3 holders — while 23 added to existing stakes and 21 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.44M. The largest seller was Newtyn Management, cutting an estimated $2.33M.
- 81 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2018, up from 78 in Q4 2017.
- Funds reported $61.4M of Merrimack Pharmaceuticals, Inc. stock for Q1 2018, down 17% quarter-over-quarter.
- 15 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2018 and 12 closed out, a net change of +3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2018 was Renaissance Technologies, an estimated $2.44M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2018 was Newtyn Management, an estimated $2.33M sold.
Based on aggregated 13F filings for Q1 2018.